JP6937309B2 - ハイブリッドプロモーターおよびその使用 - Google Patents

ハイブリッドプロモーターおよびその使用 Download PDF

Info

Publication number
JP6937309B2
JP6937309B2 JP2018536777A JP2018536777A JP6937309B2 JP 6937309 B2 JP6937309 B2 JP 6937309B2 JP 2018536777 A JP2018536777 A JP 2018536777A JP 2018536777 A JP2018536777 A JP 2018536777A JP 6937309 B2 JP6937309 B2 JP 6937309B2
Authority
JP
Japan
Prior art keywords
sequence
protein
seq
cells
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018536777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503179A5 (enExample
JP2019503179A (ja
Inventor
ティー． マクグルー，ジェフリー
ティー． マクグルー，ジェフリー
エス． スミディット，ポーライン
エス． スミディット，ポーライン
オン，イーチェン
Original Assignee
ジャスト−エヴォテック バイオロジックス、インコーポレイテッド
ジャスト−エヴォテック バイオロジックス、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャスト−エヴォテック バイオロジックス、インコーポレイテッド, ジャスト−エヴォテック バイオロジックス、インコーポレイテッド filed Critical ジャスト−エヴォテック バイオロジックス、インコーポレイテッド
Publication of JP2019503179A publication Critical patent/JP2019503179A/ja
Publication of JP2019503179A5 publication Critical patent/JP2019503179A5/ja
Application granted granted Critical
Publication of JP6937309B2 publication Critical patent/JP6937309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018536777A 2016-01-27 2017-01-26 ハイブリッドプロモーターおよびその使用 Active JP6937309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662388391P 2016-01-27 2016-01-27
US62/388,391 2016-01-27
PCT/US2017/015130 WO2017132376A1 (en) 2016-01-27 2017-01-26 Hybrid promoter and uses thereof

Publications (3)

Publication Number Publication Date
JP2019503179A JP2019503179A (ja) 2019-02-07
JP2019503179A5 JP2019503179A5 (enExample) 2021-04-22
JP6937309B2 true JP6937309B2 (ja) 2021-09-22

Family

ID=58044162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536777A Active JP6937309B2 (ja) 2016-01-27 2017-01-26 ハイブリッドプロモーターおよびその使用

Country Status (5)

Country Link
US (1) US11028410B2 (enExample)
EP (1) EP3408397B1 (enExample)
JP (1) JP6937309B2 (enExample)
ES (1) ES2823173T3 (enExample)
WO (1) WO2017132376A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11098310B2 (en) * 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US20240035037A1 (en) * 2016-01-27 2024-02-01 Just-Evotec Biologics, Inc. Transposon-based vectors and uses
US12421524B2 (en) * 2018-09-24 2025-09-23 Merck Sharp & Dohme Llc Expression vectors for eukaryotic expression systems
PT115073A (pt) 2018-10-09 2020-05-29 Inst De Biologia Molecular E Celular Ibmc Ácido nucleico para ativar a expressão e a produção de proteínas
KR102937659B1 (ko) 2020-02-19 2026-03-10 우시 바이올로직스 아일랜드 리미티드 강화된 발현 시스템 및 그 사용방법
WO2022204067A1 (en) * 2021-03-24 2022-09-29 Dna Twopointo Inc. Tetracycline-inducible expression systems
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
CN122349567A (zh) 2023-12-11 2026-07-07 济世易为生物有限公司 利用反式剪接和拆分型选择标记的蛋白质表达
EP4711442A1 (en) 2024-09-15 2026-03-18 Quantitative Biosciences, Inc. Microfluidic chip for the parallel culture of microbial biosensor strains

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE135045T1 (de) 1988-07-23 1996-03-15 Delta Biotechnology Ltd Sekretorische leader-sequenzen
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6022952A (en) 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
JP4475814B2 (ja) 1998-11-20 2010-06-09 扶桑薬品工業株式会社 タンパク質発現ベクターとその使用
CA2368068A1 (en) 1999-03-18 2000-09-21 Steven M. Ruben 27 human secreted proteins
US20050005310A1 (en) 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
GB2355459B (en) 1999-11-29 2001-09-26 Isis Innovation A dominant conditional lethal genetic system
DK1332222T3 (da) 2000-11-03 2009-07-06 Genentech Inc Stofskifteændringer i fermenteringer der udtrykker rekombinante proteiner
US20050019925A1 (en) 2002-11-14 2005-01-27 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
ATE399872T1 (de) 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
WO2005016130A2 (en) 2003-08-14 2005-02-24 Wyeth Recombinant lubricin molecules and uses thereof
KR20050022071A (ko) 2003-08-26 2005-03-07 삼성에스디아이 주식회사 플라즈마 디스플레이 패널
EP1819812B1 (en) 2004-12-02 2012-05-30 Merck Serono SA The lupac bifunctional marker and its use in protein production
WO2006063292A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
CN101405297A (zh) 2006-02-03 2009-04-08 惠氏公司 Lingo-1结构
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
CA2656598A1 (en) 2006-08-07 2008-02-21 Avigenics, Inc. Hybrid promoters
FR2910490B1 (fr) 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
KR100884214B1 (ko) 2007-04-04 2009-02-19 주식회사 마크로젠 Ｃａｅｖ-계 벡터 시스템
AU2008271658B8 (en) 2007-06-29 2013-07-04 F. Hoffmann-La Roche Ag Promoter
PT2592148T (pt) 2007-10-12 2018-11-12 Hoffmann La Roche Expressão proteica de múltiplos ácidos nucleicos
WO2009053368A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
SI2796466T1 (en) 2007-12-07 2018-01-31 Zymogenetics, Inc. Molecules of Humanized Specifics Specifiable for IL-31
US8795981B2 (en) 2008-08-08 2014-08-05 Molecular Devices, Llc Cell detection
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
GB201004143D0 (en) 2010-03-12 2010-04-28 Isis Innovation Promoter sequence for DNA and viral vectors
RU2661764C2 (ru) 2011-05-27 2018-07-19 Эббви Байотекнолоджи Лтд., Композиции и способы на основе dac hyp
EP2741773A1 (en) 2011-08-08 2014-06-18 AbbVie Biotherapeutics Inc. Methods of treating progressive forms of multiple sclerosis
CA2857298A1 (en) 2011-11-30 2013-06-06 Abbvie Biotherapeutics Inc. Vectors and host cells comprising a modified sv40 promoter for protein expression
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201700169PA (en) 2011-12-22 2017-02-27 Hoffmann La Roche Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
KR101494072B1 (ko) 2012-03-12 2015-02-17 한화케미칼 주식회사 변이된 글루타민 합성효소 유전자를 포함하는 벡터 및 이를 이용한 목적 단백질의 생산방법
AR091116A1 (es) 2012-05-22 2015-01-14 Bristol Myers Squibb Co Anticuerpos biespecificos y sus metodos de uso
EP2674495A1 (en) 2012-06-14 2013-12-18 Sanofi CHO expression system
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
SG11201502801RA (en) * 2012-10-10 2015-06-29 Chugai Pharmaceutical Co Ltd Method for establishing modified host cell
US9290552B2 (en) 2012-12-21 2016-03-22 Dna Twopointo, Inc. Fluorescent and colored proteins and methods for using them
CA2904146C (en) 2013-03-08 2023-03-21 Neuclone Biologics Pty Ltd A cell expression system
EP3683314A1 (en) 2013-10-07 2020-07-22 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
US10927384B2 (en) 2014-04-09 2021-02-23 Dna Twopointo Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
HUE052552T2 (hu) 2014-04-09 2021-05-28 Dna Twopointo Inc Javított nukleinsav-konstrukciók eukarióta génexpresszióhoz
US11280790B2 (en) 2016-10-04 2022-03-22 Svar Life Science Ab System and products for improved quantification of ADCC activity
US12534502B2 (en) 2016-10-04 2026-01-27 Svar Life Science Ab FGF21 responsive reporter gene cell line

Also Published As

Publication number Publication date
ES2823173T3 (es) 2021-05-06
EP3408397A1 (en) 2018-12-05
US20190055580A1 (en) 2019-02-21
US11028410B2 (en) 2021-06-08
EP3408397B1 (en) 2020-07-15
JP2019503179A (ja) 2019-02-07
WO2017132376A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
EP3408397B1 (en) Hybrid promoter and uses thereof
US11685933B2 (en) Inducible expression from transposon-based vectors and uses
JP2019503179A5 (enExample)
US10975151B2 (en) ASPGR antibodies and uses thereof
US11692193B2 (en) Expression from transposon-based vectors and uses
JP2026063391A (ja) 互いに連結された２つの抗原結合ドメインを含む抗原結合分子
CN107312796A (zh) 蛋白质的生产方法
WO2020260327A1 (en) Mammalian cell lines with sirt-1 gene knockout
JP2022537202A (ja) 所定の構成の複数の発現カセットの標的指向性組込みによって多価二重特異性抗体発現細胞を作製するための方法
JP2022537334A (ja) 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法
US20190346456A1 (en) High throughput antibody variant screening method
JP2017530718A (ja) 宿主細胞における異種由来遺伝子の発現を改善するためのプロモーター及び調節エレメント
JP2023179537A (ja) 改変されたヒト可変ドメイン
US20240035037A1 (en) Transposon-based vectors and uses
US20190031752A1 (en) Method for Producing Antibodies
TW202321312A (zh) 包含基於ｍｈｃ或ｍｈｃ樣蛋白的異源二聚體的二價雙特異性嵌合抗體
CN101180316B (zh) 在哺乳动物宿主细胞中高水平表达重组抗体
WO2025128343A1 (en) Protein expression using trans-splicing and split selectable markers
JP2010536345A (ja) 新規な方法および細胞系
HK40040827A (en) Modulating lactogenic activity in mammalian cells
WO2025202147A1 (en) Interleukin-7 immunoconjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210830

R150 Certificate of patent or registration of utility model

Ref document number: 6937309

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250